Delivering cancer treatment at home has the potential to enhance patient experience and satisfaction while maintaining or improving cancer care quality, to increase the efficiency and productivity of cancer care delivery across Penn’s health system, and to lower health care spending for payers and patients.
We apply the latest science to create, test, and scale solutions to address the most intractable problems in cancer care delivery.
We are change agents dedicated to designing, testing, scaling and disseminating innovations in cancer care.
The Radiotherapy Comparative Effectiveness Consortium’s National Pragmatic Randomized Trial of Proton Therapy vs. Photon Therapy for Breast Cancer
The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a clinical study comparing two FDA approved radiation therapies — PHoton Therapy vs. PRoton Therapy — for the treatment of breast cancer and enrolls at over 70 radiation therapy practice sites nationwide.
Connected Health Approaches to Improve Serious Illness Communication Among Patients with Incurable Cancer
Providing clinicians with patient-reported symptoms and remotely-monitored functional status will help clinicians better identify palliative care needs and increase rates of documented Serious Illness Conversations.
Implementation Strategies for Monitoring Adherence in Real Time (iSMART) for Oral Anticancer Therapies
By combining innovations from behavioral economics and machine learning with highly accessible text-messaging platforms, this initiative has the potential not only to identify scalable, patient-targeted strategies for improving adherence to oral therapies, but also to transform the way cancer care is delivered and implemented.
Penn and Pfizer are partnering to conduct a real-world evaluation of FDA-approved targeted therapies in cancer. We are developing approaches to accelerate the use of real-world evidence in cancer care.